Ranolazine in Ischemic Cardiomyopathy
| Status: | Completed |
|---|---|
| Conditions: | Angina, Cardiology, Pulmonary |
| Therapuetic Areas: | Cardiology / Vascular Diseases, Pulmonary / Respiratory Diseases |
| Healthy: | No |
| Age Range: | 18 - Any |
| Updated: | 9/8/2018 |
| Start Date: | April 2011 |
| End Date: | April 2014 |
Ranolazine in Ischemic Cardiomyopathy Patients With Persistent Chest Pain or Dyspnea Despite Conventional Therapy: A Cross-Over Study
Patients with ischemic cardiomyopathy may continue to experience persistent chest pain and
shortness of breath despite conventional medical therapy and/or revascularization. The
purpose of this study is to determine the efficacy of taking Ranexa versus placebo in
patients with ischemic (due to blockages) cardiomyopathy treated with optimal conventional
medical therapy and/or percutaneous revascularization.
shortness of breath despite conventional medical therapy and/or revascularization. The
purpose of this study is to determine the efficacy of taking Ranexa versus placebo in
patients with ischemic (due to blockages) cardiomyopathy treated with optimal conventional
medical therapy and/or percutaneous revascularization.
Inclusion Criteria:
1. Ischemic cardiomyopathy patients on optimal medical treatment. Optimal medical
treatment is defined as the continued symptoms of chest pain or dyspnea despite
treatment with 2 antiischemic agents (beta blockers, CCB or nitrates). Unless
contraindicated, all cardiomyopathy patients should be treated with a beta blocker and
an ACEI/ARB.
2. Anginal chest pain or dyspnea
3. Documentation of non treatable or optimally treated coronary artery disease
4. Ejection Fraction of less than or equal to 40%
Exclusion Criteria:
1. Less than 18 years of age
2. Pregnant or breast feeding
3. Patients with non ischemic cardiomyopathy
We found this trial at
1
site
Click here to add this to my saved trials
